|
|
Article: Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results in a Phase 3 Transient Insomnia Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- October 23, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* SILENOR(TM) Demonstrates Statistically Significant Improvement vs. Placebo in Transient Insomnia * Primary Endpoint of Latency to Persistent Sleep (LPS) Demonstrates Sleep Onset Action of SILENOR(TM) * Represents Second Phase 3 Clinical Trial of SILENOR(TM) to Demonstrate Positive Results in the Treatment of Insomnia. Two Remaining Phase 3 Trials Will be Reported by End of 2006
SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. today announced positive results from the company's Phase 3 clinical trial evaluating SILENOR(TM) (doxepin HCl) in adults with transient insomnia. SILENOR(TM) demonstrated statistically significant improvements ...